Search - tctmd.com

Displaying 601 - 620 of 987

Sort: Relevancy | Date

News Daily News

Repeat Target-Lesion PCI: An Option for Public Reporting?

Michael O'Riordan

October 25, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

Michael O'Riordan

October 17, 2019

News Conference News TCT 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Yael L. Maxwell

September 29, 2019

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

Todd Neale

September 29, 2019

Presentation TCT 2019

Endovascular Renal Sympathetic Denervation to Improve Heart Failure With Reduced Ejection Fraction: The IMPROVE HF-I Study

Presenter: Joost Daemen

September 27, 2019

Presentation TCT 2019

Hong Kong Presents: TAVR in a Patient With Very Low Ejection Fraction

Presenter: Kam-Tim Chan

September 26, 2019

Presentation TCT 2019

Driving Quality in PCI: The Benefits of Complete Revascularization for Improvements in Ejection Fraction and Patient Quality of Life

Presenter: Ehtisham Mahmud

September 26, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

Todd Neale

September 13, 2019

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

L.A. McKeown

September 13, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

Advertisement

Repeat Target-Lesion PCI: An Option for Public Reporting?

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

Endovascular Renal Sympathetic Denervation to Improve Heart Failure With Reduced Ejection Fraction: The IMPROVE HF-I Study

Hong Kong Presents: TAVR in a Patient With Very Low Ejection Fraction

Driving Quality in PCI: The Benefits of Complete Revascularization for Improvements in Ejection Fraction and Patient Quality of Life

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content